Effect of transdermal hormone therapy on platelet haemostasis in menopausal women

• Main Authors: Grzegorz Stachowiak, Tomasz Pertyński, Magdalena Pertyńska-Marczewska
• Format: Article
• Language: English
• Published: Institute of Rural Health 2015-02-01
• Series: Annals of Agricultural and Environmental Medicine
• Subjects: transdermal hormone therapy;platelets;Menopause;GP IIb/IIIa
• Online Access: http://journals.indexcopernicus.com/fulltxt.php?ICID=1141389
• ISSN: 1232-1966; 1898-2263

[b]Introduction[/b]. Despite the undeniably positive effect on the quality of life of menopausal women, menopausal hormone therapy (HT) also has negative side-effects, which include, among others, thromboembolic complications. [b]objective[/b]. To assess the effect of a popular type of this therapy – transdermal HT on platelet hemostasis, which plays a significant role in intravascular coagulation. [b]Materials and method[/b]. The study group consisted of 92 postmenopausal women: 1) group G1 (n=30), treated with transdermal HT (17β-estradiol 50 μg/day plus NETA 170 μg/day); 2) group G2 (n=31), treated with the above transdermal HT and low dosage of acetylsalicylic acid (ASA); 3) control group P (n=31). All the women qualified for the study had two or more risk factors for arterial thrombosis, such as: smoking, hypertension, visceral obesity, hypercholesterolaemia, hypertriglyceridaemia, elevated levels of PAI-1, and increased fibrinogen, increased activity of coagulation factor VII. Results. After three months of therapy, in the G1 group there was a decrease in platelet count (p = 0.004) and a decrease in GP IIb/IIIa – a platelet receptor for fibrinogen (p = 0.022). In the G2 group, no changes in the tested parameters were observed. conclusions. 1) Transdermal HT in the form of combined, estrogen-progestogen patches favourably modifies platelets haemostasis, reversing the adverse effects that occur after menopause. 2) The use of low ASA doses as a thromboprophylaxis in short-term transdermal HT is not necessary.